# MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing

> **NCT04574752** · — · UNKNOWN · sponsor: **Rothman Institute Orthopaedics** · enrollment: 163 (actual)

## Conditions studied

- Staphylococcus Aureus
- Next Generation Sequencing
- Total Joint Arthroplasty

## Interventions

- **DIAGNOSTIC_TEST:** next generation sequencing

## Key facts

- **NCT ID:** NCT04574752
- **Lead sponsor:** Rothman Institute Orthopaedics
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-30
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574752, "MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04574752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*